US-based health care company Baxter has launched HDx enabled hemodialysis (HD) therapy, THERANOVA to provide enhanced treatment within the existing healthcare infrastructure.
HDx, or expanded hemodialysis uses Baxter’s new THERANOVA dialyzer to expand the range of molecules that can be filtered from the blood during therapy, thereby forming a filtration profile that replicates the natural kidney.
THERANOVA dialyzers are developed to treat chronic and acute renal failure by hemodialysis.
Baxter Renal corporate vice-president and president Giuseppe Accogli said: ''Through HDx enabled by THERANOVA, Baxter is introducing a major advancement in hemodialysis, an area that has seen little improvement in recent years.
''We expect HDx enabled by THERANOVA to advance hemodialysis care for millions of patients around the world.''
Current hemodialysis therapies with the conventional HD using a low-flux or high-flux dialyzer and hemodiafiltration (HDF) effectively removes urea and smaller middle molecules but cannot remove large middle molecules.
The large middle molecules are known to affect biological functions such as inflammation and cardiovascular risk as well as causing higher mortality in chronic kidney disease patients.
THERANOVA was recently proven effective in a study for the removal of middle molecules as well as offer better performance of high-volume HDF for large solutes, with moderate albumin removal.
HDx enabled by THERANOVA is easy to use and is compatible with most HD machines which allows the clinics to offer HDx therapy in the existing infrastructure without requiring special equipment and added clinic workflow.
Image: Baxter launches HDx therapy enabled by THERANOVA. Photo: courtesy of Business Wire.